• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions

    12/31/24 11:55:42 AM ET
    $EFSH
    $LIPO
    Professional Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EFSH alert in real time by email

    New York, NY, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is proud to announce a series of notable transactions completed in December 2024, further solidifying its reputation as a trusted partner for fast-growing companies across diverse industries.

    Spartan Capital facilitated a private placement valued at approximately $17 million for Burkhan World Investments. Headquartered in Washington, D.C., and Abu Dhabi, Burkhan blends strategic foresight with societal impact across sectors including telecom, energy, technology, and food security. Under the leadership of founder Shahal Khan, Burkhan continues to advance equity-based economic systems and sustainability-focused initiatives.

    The firm also assisted Blaize in completing a $13 million private placement. Blaize specializes in AI processing solutions for high-performance computing across data centers, delivering cutting-edge technology that supports real-time insights and efficiency.

    In addition, Spartan Capital served as the sole placement agent for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), facilitating a $1.72 million private placement. This transaction supports Lipella's mission to advance its clinical pipeline and address significant unmet medical needs under the leadership of CEO Dr. Jonathan Kaufman.

    Earlier in December, Spartan Capital also served as the sole placement agent for 1847 Holdings LLC (NYSE:EFSH) in their $11.424 million private placement. This funding will support 1847 Holdings' acquisition of a Las Vegas-based millwork, cabinetry, and door manufacturer, marking a transformative step in their growth strategy.

    These transactions cap off a year of significant achievements for Spartan Capital, which successfully closed numerous deals across various industries, solidifying its standing in the capital markets. CEO John Lowry expressed gratitude to the firm's clients and partners for their collaboration and acknowledged the NYSE and Nasdaq for providing platforms that enable exceptional value delivery.

    As Spartan Capital looks ahead to 2025, the firm remains committed to delivering innovative, client-focused investment banking solutions while building on the momentum of a successful 2024. As Spartan Capital closes the chapter on 2024 and looks ahead, the firm is excited about the opportunities and growth awaiting in 2025.

    About Spartan Capital Securities, LLC

    Spartan Capital Securities, LLC is a full-service, integrated financial services firm providing tailored investment banking solutions to high-net-worth individuals and institutions. With deep market expertise and a steadfast commitment to client success, Spartan Capital continues to set the standard for excellence in the financial industry.

    Contact:

    Spartan Capital Securities, LLC

    45 Broadway, 19th Floor

    New York, NY 10006

    [email protected]



    Primary Logo

    Get the next $EFSH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EFSH
    $LIPO

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $EFSH
    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

      PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ("Cook MyoSite") to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, "We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC

      6/4/25 8:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

      Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 (liposomal tacrolimus oral rinse) for the treatment of Oral Lichen Planus (OLP) will be presented at the 2025 joint international meeting of the American Academy of Oral Me

      5/15/25 9:00:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

      Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at

      4/23/25 8:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFSH
    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      4/7/25 7:16:11 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/17/25 8:12:52 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/11/25 8:01:27 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFSH
    $LIPO
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by 1847 Holdings LLC

      S-1/A - 1847 Holdings LLC (0001599407) (Filer)

      6/5/25 4:08:21 PM ET
      $EFSH
      Professional Services
      Consumer Discretionary
    • 1847 Holdings LLC filed SEC Form 8-K: Other Events

      8-K - 1847 Holdings LLC (0001599407) (Filer)

      5/20/25 5:11:30 PM ET
      $EFSH
      Professional Services
      Consumer Discretionary
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      5/16/25 4:05:53 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EFSH
    $LIPO
    Leadership Updates

    Live Leadership Updates

    See more
    • 1847 Encourages Shareholders to Vote in the Upcoming Annual Shareholder Meeting on June 25th

      NEW YORK, NY / ACCESSWIRE / June 21, 2024 / 1847 Holdings LLC ("1847" or the "Company") (NYSE:EFSH), a holding company specializing in identifying over-looked, deep value investment opportunities in middle market businesses, encourages shareholders to vote in the upcoming shareholder meeting.The upcoming 2024 Annual Meeting of Stockholders will be held on June 25, 2024, at 2:00 p.m. Eastern Time. 1847's stockholders at the close of business on the record date of April 26, 2024 are encouraged to vote their shares as soon as possible before 9 a.m. Eastern Time on June 24, 2024. Stockholders can exercise their votes online, via telephone or by mail.The Annual Meeting will be held virtually at h

      6/21/24 11:45:00 AM ET
      $EFSH
      Professional Services
      Consumer Discretionary
    • 1847 Holdings Appoints Finance Veteran Michele A. Chow-Tai as Independent Director

      NEW YORK, NY / ACCESSWIRE / August 11, 2023 / 1847 Holdings LLC ("1847" or the "Company") (NYSE:EFSH), a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, announced today that it has appointed finance veteran Michele A. Chow-Tai, to its Board of Directors as an independent board member. Ms. Chow-Tai was also appointed to the Audit Committee and the Nominating and Corporate Governance Committee.Ms. Chow-Tai is an experienced professional in global banking and financial services with more than 32 years of industry expertise. For nearly seven years, she has been leadi

      8/11/23 8:30:00 AM ET
      $EFSH
      Professional Services
      Consumer Discretionary
    • 1847 Appoints Glyn C. Milburn as Vice President of Operations

      NEW YORK, NY / ACCESSWIRE / February 24, 2023 / 1847 Holdings LLC ("1847" or the "Company") (NYSE:EFSH), a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, today announced that it has appointed Glyn C. Milburn as Vice President of Operations. Additionally, the Company announced that Eric VanDam resigned from his position as Chief Operating Officer to pursue an opportunity closer to where he resides in Michigan and not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.Mr. Milburn has been a member of

      2/24/23 8:30:00 AM ET
      $EFSH
      Professional Services
      Consumer Discretionary

    $EFSH
    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:09:22 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:00:15 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 1847 Holdings LLC

      SC 13G - 1847 Holdings LLC (0001599407) (Subject)

      11/5/24 4:01:02 PM ET
      $EFSH
      Professional Services
      Consumer Discretionary

    $EFSH
    $LIPO
    Financials

    Live finance-specific insights

    See more
    • 1847 Holdings Engages Two Roads Advisors to Facilitate Sale of Wolo Manufacturing Corp.

      NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / 1847 Holdings LLC (NYSE:EFSH) ("1847 Holdings" or the "Company") today announced the engagement of Two Roads Advisors, a boutique investment bank specializing in mergers and acquisitions, to manage the sale process for its subsidiary, Wolo Manufacturing Corp. ("Wolo").Wolo is a leading manufacturer and distributor of vehicle horns and safety products, offering a comprehensive range of electric and air horns for trucks, marine vessels, motorcycles, and industrial equipment. The company also provides a broad array of vehicle emergency and safety warning lights for cars, trucks, industrial equipment, and emergency vehicles.The sale of Wol

      1/16/25 8:30:00 AM ET
      $EFSH
      Professional Services
      Consumer Discretionary
    • 1847 Holdings Announces Special Dividend of Series E Preferred Shares

      NEW YORK, NY / ACCESSWIRE / December 31, 2024 / 1847 Holdings LLC (NYSE:EFSH) ("1847 Holdings" or the "Company") today announced that its Board of Directors has declared a special dividend of newly designated Series E Preferred Shares. Each holder of the Company's Common Shares as of the record date of January 10, 2025 will receive one (1) Series E Preferred Share for each Common Share held.Each outstanding Series E Preferred Share will have 1,000,000 votes per share and will vote together with the outstanding Common Shares as a single class exclusively with respect to certain proposals to be presented at an upcoming shareholder meeting. All Series E Preferred Shares that are not voted prior

      12/31/24 4:15:00 PM ET
      $EFSH
      Professional Services
      Consumer Discretionary
    • 1847 Holdings CEO Provides Letter to Shareholders

      NEW YORK, NY / ACCESSWIRE / December 31, 2024 / 1847 Holdings LLC (NYSE:EFSH) ("1847 Holdings" or the "Company"), today provided the following letter to shareholders from the Company's CEO, Ellery Roberts:To our valued shareholders,As 2024 draws to a close, I am pleased to reflect on what we view as a transformative year for 1847 Holdings, as we executed a series of strategic initiatives designed to position the Company for sustained growth and maximize shareholder value over the long term.A cornerstone of our growth strategy has been identifying and acquiring businesses that we believe have compelling cash earnings potential at attractive valuations. We strive to consistently target acquisi

      12/31/24 8:30:00 AM ET
      $EFSH
      Professional Services
      Consumer Discretionary

    $EFSH
    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      5/15/24 4:39:19 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/19/24 6:21:08 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care